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Background
Left ventricular noncompaction (LVNC) is a diagnosis
often made at imaging with uncertain prognostic value.
Jenni echocardiogram and Petersen cardiac MR (CMR)
criteria utilize a single long-axis view to quantify the
maximal ratio of noncompacted to compacted myocar-
dial thickness, but these have not been shown to corre-
late with clinical status or disease progression.
Quantitation of the trabecular mass is now simple to
perform using advanced post-processing tools. Prior stu-
dies demonstrated that elevated LV trabeculated mass
helps differentiate patients with LVNC from healthy
controls and patients with other non-ischemic cardio-
myopathies, but distinguishing patients with morpholo-
gic LVNC (M-LVNC) from those with clinically
significant LVNC (CS-LVNC) remains problematic. The
purpose of this study was to evaluate the performance
of trabecular mass quantification at CMR to differentiate
patients with CS-LVNC and M-LVNC.
Methods
Retrospective analysis of 36 consecutive patients with a
CMR meeting Petersen’s criteria and an available echo-
cardiogram. Two independent observers quantified non-
compacted and compacted myocardial mass at end-
diastole on QMass 7.6 (Medis, Leiden, Netherlands)
using bright blood short-axis cine images. The noncom-
pacted myocardial mass index (NCMMI) was calculated
by dividing trabecular volume by body surface area and
multiplying by 1.05 g/mL, the density of myocardium.
CS-LVNC was defined by a clinical history of heart fail-
ure, ventricular arrhythmia, or cardioembolic event.
Two-tailed t-tests were applied to compare NCMMI
between groups. Subgroup analysis was performed by
excluding subjects with negative echocardiograms by
Jenni criteria and an ejection fraction (EF)>55%. Recei-
ver operating characteristic (ROC) analysis was used to
estimate cutoff values, sensitivities, and specificities.
Interobserver agreement was assessed using the intra-
class correlation coefficient (ICC).
Results
22 patients met criteria for CS-LVNC (50% male, 45–
years-old) versus 14 patients with M-LVNC (57.1%
male, 44–7 years-old). Those with CS-LVNC exhibited
significantly greater NCMMI compared to those with
M-LVNC (60.8 vs 47.2 mL, p= 0.020). ROC analysis
demonstrated fair discrimination between CS-LVNC
and M-LVNC (AUC 0.74, p=0.018), which significantly
improved after excluding 11 patients with EF≥55%
(AUC 0.87, p=0.002) and even further after excluding an
additional 10 patients with negative echocardiograms
(AUC 0.96, p=0.003) yielding ideal cutoff values and test
characteristics presented in Table 1. Interobserver agree-
ment was excellent for NCMMI measurements
(ICC=0.85, p<0.001). Ratios of noncompacted to com-
pacted mass and global myocardial mass were not sig-
nificantly different between patients with CS-LVNC and
M-LVNC (P≥0.05).
Conclusions
Trabecular mass quantification at CMR provides an
accurate and reliable means of identifying patients with
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Table 1 ROC Analysis of NCMMI for CS-LVNC vs. M-LVNC.
All patients (n=36) EF<55% (n=25) EF<55% and negative echo (n=15)
AUC 0.74 0.87 0.96
P-value 0.018 0.002 0.003
Ideal Cutoff Value (mL) 54.0 53.5 54.8
Sensitivity (%) 72.7 100 100
Specificity (%) 71.4 70.0 83.3
PPV (%) 80.0 83.3 90.0
NPV (%) 62.5 100 100
Figure 1 Mid-chamber segments of two patients with LVNC by Petersen criteria. Patient A has M-LVNC and NCMMI of 29.9 g/m2 vs.
patient B with CS-LVNC and NCMMI of 102.6 g/m2. Images A2 and B2 depict epicardial contours (green circle), endocardial contours (red circle),
and myocardial/trabeculated mass (green coloring).
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